Breaking 23:00 Killer Robots: Guterres Warns of Growing Threat Posed by Autonomous Weapons 22:30 Bharat Semi: Indian Chip Startup Raises $24 Million to Develop AI-Powered Sensors 22:15 Germany: EU Approves UniCredit’s Takeover of Commerzbank in Major Banking Consolidation Move 22:00 Yemen: Riyadh Dismisses Commander of the Military Coalition 21:30 Nvidia: Why Jensen Huang's Departure Could Shake the Entire AI Industry 21:00 Qatar Football: Walid Regragui Emerges as a Leading Candidate for National Team Coaching Job 20:30 Casablanca: Two Minors Sent to Child Protection Centre After Al Jabr School Terror Scare 20:00 Belgium: Romelu Lukaku Announces Retirement From International Football After 16 Years With the National Team 19:30 US Military Reinforcement: Third Aircraft Carrier Arrives in the Middle East Ahead of Trump’s China Summit 19:00 Morocco: Tomato Prices Remain High Despite Suspension of Exports to African Markets 18:30 Yemen: Houthis Advance Within 60 Kilometers of Aden as Government Reinforces Defences 18:00 Happy Passports Index 2026: Morocco Scores 29.7 Points and Ranks 49th 17:30 Casablanca: Building Collapse in Bouchentouf Damages Shops and Three Cars 17:00 AFCON 2027: Morocco Prepare for Crucial Niger Encounter With Qualification in Sight 16:30 South Africa: Seven Western Countries Warn of Rising Kidnapping Threat 16:09 Morocco: ACAPS Seeks Stronger Powers to Prevent Insurance Sector Crises 16:01 Brazil: Carlo Ancelotti Admits More Work Is Needed to Restore the National Team's Competitiveness 16:00 Apple Launches New App: Studying How People Use AI for Health 15:30 Morocco: MP Calls for Cigarette Prices to Reach 100 Dirhams per Pack 15:00 France vs Turkey: Zinédine Zidane Returns to Bordeaux as Les Bleus Secure Nations League Quarter-Final Spot 14:30 South Korea: AI Cheating Fears Prompt Tighter Security Ahead of University Entrance Exam 14:00 AI and Climate Change: UN Warns of Major Opportunities and Growing Environmental Risks 13:45 Israel’s Political Crisis: Eisenkot Accuses Netanyahu of Threatening Democracy 13:30 Anthropic: Three Major Challenges Ahead of Its Potential Stock Market Debut 13:15 GTA VI: Miami Transforms Into Vice City Ahead of the Highly Anticipated Launch 13:00 Morocco: Fuel Prices Drop as Gasoline and Diesel Become Cheaper at the Pump 12:45 Lebanon: US Considers Replacing UNIFIL With Fewer Than 100 International Observers 12:36 OPPO Unveils Photo and AI Innovations in Its New Find X10 Series 12:30 UK: Barrister Suspended for Four Months Over Antisemitic Social Media Posts 12:15 Morocco-US Relations: Mike Waltz to Visit Rabat for Talks on Regional Security and Strategic Cooperation 12:00 Francophonie: Secretary-General Election Postponed by One Year Amid Institutional Reforms 11:45 Amputee Football World Cup 2026: Morocco Beat the United States 2-1 to Reach the Round of 16 10:30 South Africa: Eight Men Shot Dead in KwaZulu-Natal Province 10:15 England: Three Lions Defeat Spain 3-2 in Madrid to End Champions’ Three-Year Unbeaten Run 10:00 Gaza Winter Crisis: Four Nations Demand Entry of 150,000 Tents for Displaced Families 09:56 AS FAR Women: Fouzi Lekjaa Congratulates the Moroccan Club on Its CAF Champions League Triumph 09:45 Angela Merkel: Former German Chancellor Criticizes Disproportionate International Scrutiny of Israel 09:30 Historic Gaza Tour: 20 UN Ambassadors Inspect Hamas Underground Infrastructure 09:15 France-Morocco Security Cooperation: French Police Praise Morocco Following Four Arrests of Internationally Wanted Suspects 09:00 Morocco's Currency Market: Dirham Gains 0.9% Against the Euro as Foreign Reserves Reach MAD 515.6 Billion 08:45 Rwanda: Five European Countries Plan to Establish Migrant Return Centres 08:30 Morocco Weather Forecast for November 16, 2026: Temperatures Reach 35°C in Some Regions

Moderna begins phase 3 trial of mRNA bird flu vaccine

Wednesday 22 April 2026 - 10:00
By: Dakir Madiha
Moderna begins phase 3 trial of mRNA bird flu vaccine

Moderna has launched a phase 3 clinical trial of its mRNA based vaccine targeting pandemic bird flu, marking a significant step in efforts to prepare for potential global outbreaks. The company confirmed that the first participants have received doses of the candidate vaccine mRNA 1018, the first mRNA vaccine designed specifically for pandemic influenza to reach late stage testing.

The study aims to enroll about 4,000 healthy adults aged 18 and older across the United States and the United Kingdom. It is structured as a randomized, observer blind, placebo controlled trial to assess both safety and immune response. Around 75 percent of participants will be recruited in the United Kingdom, with priority given to individuals over 65 and poultry workers, groups considered at higher risk of exposure to avian influenza.

The trial is supported by up to 54.3 million dollars in funding from the Coalition for Epidemic Preparedness Innovations, which stepped in after US federal support was withdrawn in 2025. The Department of Health and Human Services had terminated more than 700 million dollars in contracts related to the vaccine, arguing that continued investment in the mRNA H5N1 program was not justified. The funding cuts included earlier allocations made in 2024 and early 2025, creating a gap later filled by international partners focused on pandemic readiness.

Early stage results have shown strong immune responses. In a phase 1 and 2 study involving roughly 300 healthy adults, nearly 98 percent of participants achieved protective antibody levels within 43 days after two doses. This represented a more than forty fold increase compared with baseline levels. The company also plans to use data from advanced trials of its seasonal flu vaccine to support potential regulatory approval for the pandemic candidate.

The United Kingdom portion of the study is backed by national health research institutions as part of a broader partnership between Moderna and the government. The primary completion date is expected in January 2027. The trial comes as concerns persist over the spread of H5N1 among birds and livestock, with a rising number of human infections reported, particularly among agricultural workers.

If successful, the vaccine could offer a faster and more scalable alternative to traditional egg based influenza vaccines. Public health experts view rapid production capacity as critical in responding to a pandemic, where timing can determine the scale of global impact. The mRNA approach may allow vaccines to be designed and manufactured more quickly, improving preparedness for future outbreaks.


  • Fajr
  • Sunrise
  • Dhuhr
  • Asr
  • Maghrib
  • Isha

This website, walaw.press, uses cookies to provide you with a good browsing experience and to continuously improve our services. By continuing to browse this site, you agree to the use of these cookies.